前列腺癌抗原 3 检测在前列腺癌诊断中的性能：系统评价和荟萃分析。

Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis.

机构信息

Department of Urology, Korea University College of Medicine, Seoul, Korea.

Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.

出版信息

Clin Genitourin Cancer. 2020 Oct;18(5):402-408.e5. doi: 10.1016/j.clgc.2020.03.005. Epub 2020 Mar 14.

DOI:10.1016/j.clgc.2020.03.005

PMID:32280028

Abstract

PURPOSE

To explore the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in this systematic review and meta-analysis.

PATIENTS AND METHODS

A systematic literature search of Medline, Embase, and Cochrane Library databases up to October 2019 was performed. The sensitivity, specificity, and diagnostic odds ratio with 95% confidence intervals (CIs) were calculated. The summary receiver operator characteristic graph came from individual studies. We also conducted metaregression analysis to identify the moderated factors.

RESULTS

Across 54 studies (17,575 patients), the pooled sensitivity, specificity, and diagnostic odds ratio of PCA3 were 0.71 (95% CI, 0.67-0.74), 0.68 (95% CI, 0.63-0.74), and 5.28 (95% CI, 4.28-6.51), respectively. The area under the summary receiver operator characteristic curve was 0.75 (95% CI, 0.71-0.79).

CONCLUSION

Pooled data indicated that the PCA3 test had moderate sensitivity and specificity in the diagnosis of prostate cancer. PCA3 could be used as a noninvasive method for the diagnosis of prostate cancer.

摘要

目的

在本系统评价和荟萃分析中，探索前列腺癌抗原 3（PCA3）检测用于诊断前列腺癌的诊断准确性。

患者和方法

对 Medline、Embase 和 Cochrane Library 数据库进行了系统的文献检索，检索时间截至 2019 年 10 月。计算了敏感性、特异性和诊断优势比及其 95%置信区间（CIs）。汇总受试者工作特征图来自于个体研究。我们还进行了荟萃回归分析，以确定调节因素。

结果

在 54 项研究（17575 名患者）中，PCA3 的合并敏感性、特异性和诊断优势比分别为 0.71（95%CI，0.67-0.74）、0.68（95%CI，0.63-0.74）和 5.28（95%CI，4.28-6.51）。汇总受试者工作特征曲线下面积为 0.75（95%CI，0.71-0.79）。